BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38375953)

  • 1. De novo hepatitis B infection following liver transplantation with core antibody positive grafts: The role of surface antibody status in guiding long-term prophylaxis.
    Busebee B; Myhre L; Mara K; Aqel B; Taner T; Watt KD
    Clin Transplant; 2024 Feb; 38(2):e15263. PubMed ID: 38375953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.
    Xi ZF; Xia Q; Zhang JJ; Chen XS; Han LZ; Zhu JJ; Wang SY; Qiu DK
    J Dig Dis; 2013 Aug; 14(8):439-45. PubMed ID: 23638710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis.
    Wong TC; Fung JY; Cui TY; Lam AH; Dai JW; Chan AC; Cheung TT; Chok KS; Ng KK; Lo CM
    J Hepatol; 2019 Jun; 70(6):1114-1122. PubMed ID: 30871981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver grafts from anti-hepatitis B core positive donors: a systematic review.
    Cholongitas E; Papatheodoridis GV; Burroughs AK
    J Hepatol; 2010 Feb; 52(2):272-9. PubMed ID: 20034693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft.
    Wang SH; Loh PY; Lin TL; Lin LM; Li WF; Lin YH; Lin CC; Chen CL
    Liver Transpl; 2017 Oct; 23(10):1266-1272. PubMed ID: 28691231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors.
    Chen YS; Wang CC; de Villa VH; Wang SH; Cheng YF; Huang TL; Jawan B; Chiu KW; Chen CL
    Clin Transplant; 2002 Dec; 16(6):405-9. PubMed ID: 12437618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo and apparent de novo hepatitis B virus infection after liver transplantation.
    Roche B; Samuel D; Gigou M; Feray C; Virot V; Schmets L; David MF; Arulnaden JL; Bismuth A; Reynes M; Bismuth H
    J Hepatol; 1997 Mar; 26(3):517-26. PubMed ID: 9075658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of hepatitis B virus with mutated hepatitis B surface antigen in a liver transplant recipient receiving a graft from an antibody to hepatitis B surface antigen- and antibody to hepatitis B core antigen-positive donor.
    Blaich A; Manz M; Dumoulin A; Schüttler CG; Hirsch HH; Gerlich WH; Frei R
    Transfusion; 2012 Sep; 52(9):1999-2006. PubMed ID: 22313146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
    Ueda Y; Marusawa H; Egawa H; Okamoto S; Ogura Y; Oike F; Nishijima N; Takada Y; Uemoto S; Chiba T
    Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China.
    Lei M; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG
    World J Gastroenterol; 2018 Dec; 24(48):5525-5536. PubMed ID: 30622380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
    Prieto M; Gómez MD; Berenguer M; Córdoba J; Rayón JM; Pastor M; García-Herola A; Nicolás D; Carrasco D; Orbis JF; Mir J; Berenguer J
    Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.
    Roque-Afonso AM; Feray C; Samuel D; Simoneau D; Roche B; Emile JF; Gigou M; Shouval D; Dussaix E
    Gut; 2002 Jan; 50(1):95-9. PubMed ID: 11772974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBsAg seroconversion in de novo hepatitis B virus-infected paediatric liver transplant recipients with anti-viral therapy.
    Dong C; Song Z; Sun C; Wang K; Chen J; Zhang W; Wu D; Zheng W; Yang Y; Qin H; Han C; Zhang F; Wang Z; Xu M; Zhang G; Xie E; Jiao J; Cao S; Gao W; Shen Z
    J Viral Hepat; 2022 Dec; 29(12):1099-1106. PubMed ID: 36094676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor.
    Yen RD; Bonatti H; Mendez J; Aranda-Michel J; Satyanarayana R; Dickson RC
    Am J Transplant; 2006 May; 6(5 Pt 1):1077-83. PubMed ID: 16611347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea.
    Kim KD; Lee JE; Kim JM; Lee O; Hwang NY; Rhu J; Choi GS; Kim K; Joh JW
    Clin Mol Hepatol; 2021 Oct; 27(4):603-615. PubMed ID: 34492755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
    Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.